Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 9/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.62 |
| ▸ | MAPT | P10636 | 1/20 | 0.62 |
| ▸ | TSHR | P16473 | 1/20 | 0.62 |
| ▸ | HTT | P42858 | 1/20 | 0.62 |
| ▸ | FLT3 | P36888 | 4/20 | 0.56 |
| ▸ | MIF | P14174 | 1/20 | 0.56 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.55 |
| ▸ | CA12 | O43570 | 1/20 | 0.54 |
| ▸ | CA1 | P00915 | 1/20 | 0.54 |
| ▸ | CA2 | P00918 | 1/20 | 0.54 |
| ▸ | CA9 | Q16790 | 1/20 | 0.54 |
| ▸ | GSK3B | P49841 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6220529 | 0.89 | GRM5 (0.79) | GRM5KDM4EALDH1A1MAPTTSHR | |
| SCHEMBL2391955 | 0.81 | GRM5 (0.67) | GRM5MAPTFLT3NOTUMCA12 | |
| SCHEMBL1849083 | 0.80 | GRM5 (0.67) | GRM5KDM4EALDH1A1MAPTTSHR | |
| SCHEMBL3922587 | 0.80 | GRM5 (1.00) | GRM5KDM4EALDH1A1MAPTTSHR | |
| SCHEMBL6953018 | 0.80 | FLT3 (0.77) | GRM5KDM4EALDH1A1HTTFLT3 | |
| SCHEMBL5202573 | 0.80 | FLT3 (0.72) | GRM5KDM4EFLT3MIFNOTUM | |
| SCHEMBL5224021 | 0.78 | GRM5 (1.00) | GRM5KDM4EALDH1A1MAPTTSHR | |
| SCHEMBL3922456 | 0.78 | GRM5 (1.00) | GRM5KDM4EALDH1A1MAPTTSHR | |
| SCHEMBL30795243 | 0.78 | GRM5 (1.00) | GRM5KDM4EALDH1A1MAPTTSHR | |
| SCHEMBL2398328 | 0.77 | GRM5 (0.62) | GRM5KDM4EALDH1A1MAPTTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1458708-B1 | HETEROARYL SUBSTITUTED TRIAZOLE MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR-5 | MERCK & CO INC (US) | 2007-09-26 | — | — | EP | claimed |
| US-7105548-B2 | Heteroaryl substituted triazole modulators of metabotropic glutamate receptor-5 | MERCK & CO., INC. (US) | 2006-09-12 | — | — | US | claimed |
| EP-1458708-A4 | HETEROARYL SUBSTITUTED TRIAZOLE MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR-5 | MERCK & CO INC (US) | 2005-11-16 | — | — | EP | claimed |
| US-20050020585-A1 | Heteroaryl substituted triazole modulators of metabotropic glutamate receptor-5 | MERCK SHARP & DOHME CORP. | 2005-01-27 | — | — | US | claimed |
| EP-1458708-A2 | HETEROARYL SUBSTITUTED TRIAZOLE MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR-5 | Merck & Co., Inc. (US) | 2004-09-22 | — | — | EP | claimed |
| WO-2004030637-A2 | TREATMENT OF OBESITY AND OTHER DISORDERS ASSOCIATED WITH EXCESSIVE FOOD INTAKE | MERCK & CO., INC. (US) | 2004-04-15 | — | — | WO | claimed |
| WO-2003051315-A2 | HETEROARYL SUBSTITUTED TRIAZOLE MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR-5 | MERCK & CO., INC. (US) | 2003-06-26 | — | — | WO | claimed |
| EP-1458708-B1 | HETEROARYL SUBSTITUTED TRIAZOLE MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR-5 | MERCK & CO INC (US) | 2007-09-26 | — | — | EP | disclosed |
| US-7105548-B2 | Heteroaryl substituted triazole modulators of metabotropic glutamate receptor-5 | MERCK & CO., INC. (US) | 2006-09-12 | — | — | US | disclosed |
| EP-1458708-A4 | HETEROARYL SUBSTITUTED TRIAZOLE MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR-5 | MERCK & CO INC (US) | 2005-11-16 | — | — | EP | disclosed |
| US-20050020585-A1 | Heteroaryl substituted triazole modulators of metabotropic glutamate receptor-5 | MERCK SHARP & DOHME CORP. | 2005-01-27 | — | — | US | disclosed |
| EP-1458708-A2 | HETEROARYL SUBSTITUTED TRIAZOLE MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR-5 | Merck & Co., Inc. (US) | 2004-09-22 | — | — | EP | disclosed |
| WO-2004030637-A2 | TREATMENT OF OBESITY AND OTHER DISORDERS ASSOCIATED WITH EXCESSIVE FOOD INTAKE | MERCK & CO., INC. (US) | 2004-04-15 | — | — | WO | disclosed |
| WO-2003051315-A2 | HETEROARYL SUBSTITUTED TRIAZOLE MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR-5 | MERCK & CO., INC. (US) | 2003-06-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050020585-A1 | Heteroaryl substituted triazole modulators of metabotropic glutamate receptor-5 | GRM5, GRIK5, GRIN3A | GRM5 1/4885KDM4E 2329/4885ALDH1A1 2269/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.